Markwin Maring

CF Management Rotterdam (CF) is the private equity subsidiary of Filonie Management Services BV in The Netherlands. Formerly known as Concordia Management, the firm is based in The Hague and invests and advises private equity funds, namely MeesPierson Informal Opportunity Fund BV (MPF) and Concordia Fund BV (CF).

DSM Venturing BV (DSM Venturing) is the venture capital arm of Royal DSM NV in the Netherlands founded in 2001. DSM Venturing BV is headquartered in Geleen.

FABPulous BV develops a handheld disposable plasma separation device with embedded in vitro diagnostic test capability. It offers ultra rapid plasma preparation platform that can make a defined dilution of plasma from a small volume of whole blood in seconds and integrated lateral flow IVD platform. The company’s tests provide diagnosis and benefit to the patient, as well as the healthcare sector, the insurance industry, governments and society in general. FABPulous was founded in 2008 and is headquartered in Maastricht, the Netherlands.

ACS Biomarker BV develops and commercializes cardiovascular biomarkers. The firm offers miRNA profiling services. It engages in the discovery, validation, and commercialization of biomarkers that improve diagnosis, prognosis and management of cardiac diseases. The company was founded in 2007 by Mat J. A. P. Daemen, Yigal M. Pinto and Tilman Hackeng and is headquartered in Maastricht, the Netherlands.

Arecor Ltd. provides stabilization technology solutions. The firm's products include ultra-rapid acting prandial insulin, stable aqueous glucagon, ultra concentrated insulin and additional programs. The company was founded by Paul James Davis in 2007 and is headquartered in Cambridge, the United Kingdom.

Brightlands Venture Partners is an independent regional venture capital firm headquartered in Brightlands, Netherlands. The firm was founded in 2004.

Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands.

Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016.